BioTuesdays

WB starts Axsome Therapeutics at OP; fair value estimate $48

Axsome Therapeutics

William Blair initiated coverage of Axsome Therapeutics (NASDAQ:AXSM) with an “outperform” rating and a fair value estimate of $48. The stock closed at $28.21 on Sept. 17.

Axsome Therapeutics is focused on developing novel therapies for treatment of central nervous system disorders that leverage well-characterized mechanisms of action.

The company currently has four CNS pipeline assets, with three in later-stage clinical development. Lead asset, AXS-05, is a combination therapy of dextromethorphan and bupropion, providing a multimodal mechanism of action, with known efficacy in mood disorders, writes analyst Myles Minter.

After successful completion of the Phase 2 ASCEND trial in patients with major depressive disorder (MDD), Mr. Minter said Axsome expects top-line data from the ongoing Phase 3 GEMINI trial in MDD and Phase 3 STRIDE-1 trial in treatment-resistant depression during the second half of 2019.

“Positive data from either study would be sufficient, alongside the ASCEND trial and open-label safety data, for an NDA filing,” he added.

Beyond depression, Mr. Minter said AXS-05 is being developed in Alzheimer’s disease agitation, with the Phase 2/3 ADVANCE trial expected to read out in first half 2020 after completing an internal futility analysis.

Subscribe

Sign up to our weekly BioTuesdays newsletter.

Subscribe

Sign up to our weekly BioTuesdays newsletter.